In Brief | Published:

HAEMATOLOGICAL CANCER

Quizartinib tested in patients with high-risk AML

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Cortes, J. et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30240-7 (2018)

    Download references

    Author information

    Correspondence to Peter Sidaway.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark